51.53 is a good starting point to take off a small percentage of one's position to cover basis. I believe that an acquisition of kevetrin once its true potential is realized and proven in trials is 3-4x higher than 51.53.

We will get to 51.53 just from prurisol revenue, trial advancement, and the benefits of uplisting.